Compare Smith & Nephew plc (SNN) vs Trade Desk Inc (TTD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Smith & Nephew plc vs Trade Desk Inc — how do they compare? Smith & Nephew plc trades at $27.2 (market cap $11.10B), while Trade Desk Inc trades at $12.3 (market cap $5.83B). The key difference: Smith & Nephew plc is the larger of the two by market cap, and Smith & Nephew plc pays a 2.95% dividend while Trade Desk Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Smith & Nephew plc for 120 Days and Trade Desk Inc for 72 Days on average.
| SNN | TTD | |
|---|---|---|
Market Cap | $11.10B | $5.83B |
Volume | 1,051,703 | 15,864,392 |
Sector | Health | Media |
52-Week High | $37.17 | $54.13 |
52-Week Low | $26.42 | $11.92 |
Typical Hold Time | 120 Days | 72 Days |
Enterprise Value | $14.13B | $4.78B |
Dividend Yield | 2.95% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SNN trades at $26.89, near its 52-week low, with a bearish technical signal. Revenue and net income have grown steadily, reaching $6.16B and $625M in 2025, respectively, with improving margins. Recent product launches, like the EVOS PELVIC System, aim to strengthen its medical technology portfolio. However, cash flow volatility and mixed analyst sentiment pose challenges.
The stock presents a value opportunity with reasonable valuation ratios (P/E 18.34, P/S 1.85), but risks include competitive pressures and recent CFO departure. Analyst consensus is cautious, with 65% hold ratings. Upside depends on execution of growth initiatives amid market headwinds.
The Trade Desk (TTD) trades at $12.09, down 67% year-to-date amid slowing revenue growth and increased competition. The stock shows bearish technical signals with mixed earnings performance - beating Q4 2025 and Q2 2026 estimates but missing Q1 2026. Despite strong profitability metrics including 76.87% gross margins and 15.44% ROE, the company faces headwinds from Amazon and other tech giants entering the ad-tech space, with recent workforce reductions signaling operational challenges.
While TTD maintains leadership in programmatic advertising with healthy cash flow generation, near-term outlook remains cautious due to competitive pressures and slowing growth. The stock trades at attractive valuation multiples (P/E 0.15, P/S 0.02) but requires clear catalysts to reverse the downward trend. Investors should weigh the company's strong market position against execution risks in a rapidly evolving digital advertising landscape.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →About Trade Desk Inc
The Trade Desk Inc is engaged in providing a technology platform for ad buyers. Through its cloud-based platform ad buyers can create, manage, and optimize data-driven digital advertising campaigns across ad formats and channels, including display, video, audio, in-app, native and social, on a multitude of devices. Its products include Data Management Platform, Cross-Device Targeting, Video Advertising, Mobile Advertising, and others.
Read more on TTD →
